Oppenheimer Comments On 3SBio's 1Q Revenue

3SBio Inc.'s SSRX 1Q revenue of $18.1M beat consensus estimate of $17.6M, Oppenheimer reports. “EPS of $0.15 missed consensus and our estimate by $0.02,” Oppenheimer writes. “SSRX maintained FY2011 revenue growth rate guidance of 20-30%. Pricing remains stable and we expect the lift of the work-injury restriction to boost demand for TPIAO. With a low penetration rate of ~5-10%, TPIAO has strong long-term growth potential. We expect SSRX to continue to outperform.” 3SBio closed Thursday at $18.84.